Loading stock data…
TXG
$21.07+0.15 (+0.72%)
Market ClosedLast close May 13
10x Genomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
10x Genomics, Inc. in the Healthcare sector is trading at $21.07. Wall Street consensus targets $25.00 (12 analysts), implying a +18.7% move over the next 12 months. The stock is currently 20% below its 52-week high of $26.45, remaining 21.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +18.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$21.07
Potential Downside
0%
Whystock Fair Value$21.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$25.00+18.7%
Range$20.00 – $32.00
Fundamentals
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.62%
Volume
Today's trading volume
2.04M
Recent News
1 Cash-Producing Stock on Our Watchlist and 2 We Question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?
If you are trying to work out whether 10x Genomics at around US$20.92 is still good value or already pricing in a lot of optimism, it helps to break the story into simple numbers first. The stock has fallen about 5.0% over the last week and 10.1% over the last month, yet it is still up 25.9% year to date and 116.8% over the past year. However, longer term 3 year and 5 year returns are down 59.9% and 86.1% respectively, which makes timing and valuation especially important. Recent coverage...
Why 10x Genomics (TXG) Stock Is Down Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expectations, were overshadowed by concerns about its future growth prospects.
United Natural Foods Stock Is Up 85%. One Investor Just Sold Out Completely
United Natural Foods distributes natural, organic, and conventional groceries to a wide range of North American retailers.
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.